business / news / / The Manila Times
First quarter 2026 revenues increased 19% to $3.6 billion versus first quarter 2025.
FDA approved Otarmeni as the first gene therapy for genetic hearing loss, provided free in the U.S.
KEY POINTS
- Regeneron reached a U.S. government agreement for Most-Favored-Nation pricing and tariff relief for three years.
- Dupixent received new FDA and EC approvals for chronic spontaneous urticaria in young children.
- FDA extended EYLEA HD dosing intervals up to five months for wAMD and DME.
- Regeneron and Samsung settled patent litigation, blocking EYLEA biosimilar U.S. launch until January 2027.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →